Background
==========

Osteosarcoma (OS) is the most frequent primary bone cancer in children and adolescents. It is derived from primitive mesenchymal bone-forming cells that undergo aberrant alterations in the differentiation program \[[@b1-medscimonit-22-2075]\]. The incidence of OS was reported to be 10 cases per million persons per year \[[@b2-medscimonit-22-2075]\]. Patients with OS for 10 to 20 years account for 60% of cases \[[@b3-medscimonit-22-2075]\]. With the development of pediatric oncology, orthopedic oncology, and biology, treatment of osteosarcoma now includes aggressive cytotoxic chemotherapy and local control surgery, which achieves a 5-year overall survival approaching 70--80% \[[@b4-medscimonit-22-2075]\]. However, after patients are treated with aggressive cytotoxic chemotherapy, they finally present with metastatic disease, and there are even those whose tumors recur because of its aggressive malignancy \[[@b5-medscimonit-22-2075]\]. The overall survival rate of patients with non-metastatic osteosarcoma decreases to 20% when metastases occur \[[@b6-medscimonit-22-2075]\]. In most cases, unless obvious clinical manifestations such as bone fractures and local pain were observed, the patients may not be diagnosed as having OS; therefore, OS is often found at advanced stage \[[@b7-medscimonit-22-2075]\]. In order to continue to make progress in the treatment and diagnosis of OS, it is very important to find biomarkers of osteosarcoma.

In recent years, considerable research has focussed on osteosarcoma. Zhu found that SOX9 is up-regulated in aggressive osteosarcoma tissues compared with controls by detecting the SOX9 mRNA and protein expression levels of 30 pairs of osteosarcoma and noncancerous bone tissues \[[@b8-medscimonit-22-2075]\]. It is reported that FOXM1 is over-expressed and plays an important role in development and progression in various cancers, such as lung, liver, and breast cancer \[[@b9-medscimonit-22-2075],[@b10-medscimonit-22-2075]\]. FoxM1 was found to be up-regulated in osteosarcoma tissues, which means that FoxM1may be as a valuable prognostic biomarker for osteosarcoma \[[@b11-medscimonit-22-2075]\]. Kuan et al. suggested Dual AO/EB staining is an economic and convenient method to detect apoptosis in osteosarcoma cells \[[@b12-medscimonit-22-2075]\]. However, these molecules do not treat the osteosarcoma efficiently or selectively. Therefore, there is great need for new methods to elucidate the mechanism of osteosarcoma and new therapeutics for osteosarcoma.

In this paper, microarrays were utilized to identify differentially expressed genes (DEGs) between osteosarcoma and normal cells. Significance of differential expression, functions of DEGs, and network module analysis were performed. The identified DEGs and their enriched pathways provide references for the exploration of the molecular mechanism of the development and progression of osteosarcoma. With the analysis of PPI (protein-to-protein interaction) network, we selected out key genes, which appeared to have potential to be used for clinical treatment and diagnosis of osteosarcoma in the future.

Material and Methods
====================

Data source
-----------

The gene expression profile of GSE16088 \[[@b13-medscimonit-22-2075]\] were downloaded from a public functional genomics data repository, the GEO (Gene Expression Omnibus, *<http://www.ncbi.nlm.nih.gov/geo/>*) database. A total of 17 specimens, including 3 normal samples and 14 osteosarcoma specimens, were available based on the Affymetrix Human Genome U133A Array.

Data preprocessing
------------------

We converted the probe-level data in CEL files into expression measures using the RMA function of the Affy package in R \[[@b14-medscimonit-22-2075]\]. Then, the R/Bioconductor notes package of the microarray data platform was used to map probe sets to genes. For each sample, the expression values of all probes for a given gene were reduced to a single value by taking the average expression value.

DEGs screening
--------------

Limma, the most popular method in the statistical analysis to study the DEGs, was used to compare the normal samples and osteosarcoma samples \[[@b15-medscimonit-22-2075]\]. Only the genes with the p-value adjusted of 0.01 and \|log2(fc)\|\>1 were screened out as DEGs. We also performed clustering analysis for the DEGs and drew dendrograms.

Functional enrichment analysis of the DEGs
------------------------------------------

Gene ontology (GO) analysis is a commonly used approach for functional annotation of large-scale genomic data. The KEGG pathways database is a comprehensive and recognized database involving many kinds of biochemistry pathways. To gain further insights into the function of DEGs, we used the DAVID method to perform the GO enrichment analysis and KEGG pathways enrichment analysis related with the up-regulated genes and down-regulated genes, respectively. DAVID (The Database for Annotation, Visualization and Integrated Discovery) \[[@b16-medscimonit-22-2075]\] was used to perform the Gene Ontology (GO) analysis and KEGG pathways enrichment analysis of DEGs, with a false discovery rate (FDR) less than 0.05.

EnrichmentMap \[[@b17-medscimonit-22-2075]\], a useful tool to overcome gene-set redundancy and help in the interpretation of large gene lists, was used to integrate function enrichment results by analyzing gene-sets for enrichment significance and then organizing them as a weighted similarity network to define the relationship of different biological processes.

PPI network construction analysis
---------------------------------

Recent key research on the interaction of proteins shows that they regularly form individual molecules in the interaction of many molecules and form complicated networks. In the present study, based on the 417 DEGs obtained above, the STRING online tools \[[@b18-medscimonit-22-2075]\] were used to analyzed the PPI. The combined score \>0.4 was the PPI value. Furthermore, we performed KEGG pathways enrichment analysis of the network nodes. After obtaining the PPI, the Network Analyzer plug-in \[[@b19-medscimonit-22-2075]\] of Cytoscape software was used to analyze the topology property of the networks. In addition, we performed the module analysis of the network by using the ClusterONE plug-in board, then modules with p-value \<0.01 were selected to perform the function analysis.

Results
=======

Data source and preprocessing
-----------------------------

A total of 13 272 genes from 3 normal samples and 14 osteosarcoma specimens in GSE16088 were obtained. The data before normalization and after normalization are shown in [Figure 1](#f1-medscimonit-22-2075){ref-type="fig"}. The median of different samples was almost on the same line after normalization, indicating an excellent degree of standardization.

Identification of DEGs
----------------------

Limma of R software was used to perform the differential expression analysis of 14 osteosarcoma cancer cell samples and 3 controls, with the p-value adjusted to 0.01 and \|log2(fc)\|\>1. Finally, 417 DEGs were identified, including 215 (51.56%) up-regulated and 202 (48.4%) down-regulated DEGs ([Figure 2](#f2-medscimonit-22-2075){ref-type="fig"}, [Table 1](#t1-medscimonit-22-2075){ref-type="table"}). The clustering of samples was mainly separated into 2 clusters: one was a control sample and the other was an osteosarcoma sample. The clustering of genes was mainly separated into 3 clusters: the first was the down-regulated genes of the osteosarcoma sample, the second was the up-regulated genes of the osteosarcoma sample, and the third was significantly up-regulated genes.

Functional enrichment and integrated analysis of the DEGs
---------------------------------------------------------

EnrichmentMap was used to analyze the relation between the enriched GO terms ([Figure 3](#f3-medscimonit-22-2075){ref-type="fig"}). In GO term, a total of 12 up-regulated expression genes were enriched in Cellular Component (CC), while 22 down-regulated ones were not mutually enriched in ([Table 2](#t2-medscimonit-22-2075){ref-type="table"}). Down-regulated expression proteins were enriched in the organelles concerned with energy metabolism, such as ribosomes and spliceosomes; while up-regulated expression proteins were enriched in the organelles concerned with energy metabolism such as up-regulated expression proteins were enriched in extracellular domain such as extracellular region part, while in Biological Process (BP), 17 genes were up-regulated and 40 genes were down-regulated ([Table 3](#t3-medscimonit-22-2075){ref-type="table"}). Down-regulated expression genes were mainly enriched in 4 biological processes such as positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle. Down-regulated expression proteins influence the proliferation and fission of cell since ubiquitin-protein ligase is related with the cell cycle. Some expression genes of bone development and cell adhesion were up-regulated. Meanwhile, 5 up-regulated and 8 down-regulated genes were enriched in Molecular Function (MF) ([Table 4](#t4-medscimonit-22-2075){ref-type="table"}). The 5 MFs which the up-regulated expression proteins enriched have no close connection, while 5 out of the 8 MFs which the down-regulated expression proteins enriched have close connections.

On the other hand, the metabolic pathways of the up-regulated and down-regulated genes were clearly different. The up-regulated expression genes were enriched in 6 KEGG pathways and the down-regulated expression genes were enriched in 2 KEGG pathways ([Table 5](#t5-medscimonit-22-2075){ref-type="table"}).

Network analysis
----------------

The STRING tool was used to get the PPI relationships of the 417 DEGs. The PPI with the combined score \>0.4 was selected and we gained 1006 PPI relationships and 238 nodes, accounting for 57.07% of all DEGs. The network of PPI relationships appeared to be aggregated ([Figure 4](#f4-medscimonit-22-2075){ref-type="fig"}).

Network module analysis
-----------------------

The topology property of the network is shown in [Figure 5](#f5-medscimonit-22-2075){ref-type="fig"}. The node degree distribution of the PPI was in power-law distribution according to the results shown in [Figure 5](#f5-medscimonit-22-2075){ref-type="fig"}. We screened 7 modules with 10 nodes and p-value 0.05 by using the ClusterONE plug-in board of Cytoscape ([Table 2](#t2-medscimonit-22-2075){ref-type="table"}, [Figure 6](#f6-medscimonit-22-2075){ref-type="fig"}).

Discussion
==========

Osteosarcoma is the most frequent primary bone tumor predominantly affecting children and adolescents \[[@b20-medscimonit-22-2075]\]. Patients with OS commonly are treated with aggressive cytotoxic chemotherapy and local control surgery, and the prognosis for patients is poor \[[@b21-medscimonit-22-2075]\]. In addition, patients with OS were often diagnosed at advanced stage due to the limited diagnostic methods and unclear clinical manifestations. There is an urgent need to explore the mechanism of osteosarcoma, and the knowledge gained would help develop effectively diagnoses and treatment strategies. In this study, we gained 417 DEGs upon gene expression profiling of osteosarcoma patient samples, among which the down-regulated DEGs were enriched in cell cycle pathways. CDC20, MCM, and CCNB1, the key proteins of the cell cycle, were down-regulated in module analysis of PPI, which facilitated the decline of cell proliferation. Furthermore, ECM, ITGA, and RTKin of focal adhesion were up-regulated.

Cell division cycle (CDC) proteins play important roles in the orderly progression of the cell cycle through complexing with the anaphase-promoting complex/cyclosome (APC/C) to initiate early mitosis \[[@b22-medscimonit-22-2075]\]. Kata found the over-expression of CDC20 was closely related with the poor prognosis of patients with primary non-small cell lung cancer \[[@b23-medscimonit-22-2075]\]. Wu found that CDC20 over-expression was a sign of the poor prognosis for patients with colorectal cancer \[[@b24-medscimonit-22-2075]\]. The high expression of CDC20 and MAD2 were found to predict poor prognosis in urothelial bladder cancer \[[@b25-medscimonit-22-2075]\]. Zhong-Yang Ding identified CDC20 as an independent marker for predicting the clinical outcome of gastric cancer patients because up-regulation of CDC20 was associated with aggressive progression and poor prognosis in gastric cancer \[[@b26-medscimonit-22-2075]\]. In this study, we found CDC20 was differentially expressed, suggesting that CDC20 might play an important role in the progression of osteosarcoma. The other key proteins of the cell cycle, MCM and CCNB1, were differentially expressed. It is widely acknowledged that the tumor microenvironment, consisting of not only the cancer cells and all non-malignant cells, but also the interstitial fluids and the extracellular matrix (ECM), play an important role in the progression of cancer. The deregulation of ECM proteins, inducing biochemical and biomechanical changes of cancer, was associated with the progression of cancer \[[@b27-medscimonit-22-2075]\]. Periostin and tenascin C are the key players in the ECM. The over-expression of periostin was associated with the metastatic growth of breast cancer, colon cancer, lung cancer, and pancreatic cancer \[[@b28-medscimonit-22-2075]--[@b31-medscimonit-22-2075]\]. The elevated level of tenascin C predicted squamous cell carcinoma of the head and neck \[[@b32-medscimonit-22-2075]\].

In Lustosa's study, ITGA-3 was over-expressed in tumors with lymph node and distant metastasis (III/IV-stage tumors compared with I/II tumors), which is associated with advanced-stage tumors \[[@b33-medscimonit-22-2075]\]. ITGA2 might play an important role in the progress of hepatocellular carcinoma (HCC) as the target genes of miR-128, which is underexpressed in HCC \[[@b34-medscimonit-22-2075]\]. In our study, ECM and ITGA of focal adhesion was up-regulated, suggesting that ECM and ITGA might be key proteins in the progression of osteosarcoma.

Conclusions
===========

In this study, a total of 417 DEGs were found, protein-protein interaction network was constructed, and the network module analysis of the PPI was performed. Among the identified DEGs, CDC20, MCM, and CCNB1, the key proteins of the cell cycle, were down-regulated, and ECM, ITGA, and RTKin of focal adhesion were up-regulated. Furthermore, CD20, ECM, and ITGA may play important roles in the progression of osteosarcoma. Our results may provide potential data for the exploration of the development and progression of the osteosarcoma, and might be used as biological targets for the treatment of OS.
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###### 

The top 10 up- and down-regulated genes.

  Gene symbol   logFC          Adj.P.Val   Stage
  ------------- -------------- ----------- -------
  ENPP2         5.17547995     8.55E-06    UP
  OLFML2B       5.36660264     5.06E-08    UP
  IBSP          5.417618485    0.002416    UP
  COL1A2        5.423280162    1.81E-05    UP
  A2M           5.536407729    5.52E-07    UP
  CTSK          5.887173758    1.61E-05    UP
  LUM           5.917915908    1.48E-06    UP
  MAFB          5.918869282    2.39E-10    UP
  SEPP1         6.973966588    7.43E-12    UP
  SPP1          7.053656044    3.34E-09    UP
  TRIP13        −2.678853735   5.47E-06    Down
  CTGF          −2.557084806   0.00453     Down
  DRAP1         −2.542490314   4.88E-09    Down
  PFKP          −2.409871977   0.001516    Down
  SLC7A5        −2.292679135   4.80E-05    Down
  KIAA0101      −2.263301586   7.77E-06    Down
  FHL2          −2.2235318     0.004587    Down
  FEN1          −2.219024605   4.60E-06    Down
  CCNB1         −2.186489871   0.002583    Down
  HNRNPF        −2.18591996    3.75E-05    Down

###### 

The modules of networks.

  Module name   Nodes   Density   p-value
  ------------- ------- --------- ----------
  1             29      0.399     7.99E-09
  2             21      0.5095    2.48E-05
  3             13      0.8974    0.0001
  4             12      0.7121    0.000122
  5             14      0.5055    0.001929
  6             13      0.5256    0.002855
  7             21      0.5       0.003462

###### 

The KEGG pathways of 7 modules.

  Module ranking                         KEGG pathway                                                                                Genes                                                                               FDR
  -------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------
  Module 1                               hsa04512: ECM-receptor interaction                                                          IBSP, COL4A1, ITGAV, COL6A3, COL3A1, COL1A2, COL1A1, COL5A2, COL11A1, COL5A1, FN1   5.99E-11
  hsa04510: Focal adhesion               IBSP, COL4A1, ITGAV, COL6A3, COL3A1, COL1A2, PDGFRB, COL1A1, COL5A2, COL11A1, COL5A1, FN1   1.35E-08                                                                            
  Module 3                               hsa03050: Proteasome                                                                        PSMD14, PSMB6, PSMC4, PSMC3, PSMA3, PSMD1, PSMD6, PSMA7                             2.04E-10
  Module 4                               hsa04612: Antigen processing and presentation                                               HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-G, B2M                                           6.72E-04
  hsa05330: Allograft rejection          HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-G                                                        0.004467                                                                            
  hsa05332: Graft-versus-host disease    HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-G                                                        0.00571                                                                             
  hsa04940: Type I diabetes mellitus     HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-G                                                        0.007163                                                                            
  hsa05320: Autoimmune thyroid disease   HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-G                                                        0.012942                                                                            
  hsa05416: Viral myocarditis            HLA-DRB1, HLA-A, HLA-C, HLA-B, HLA-G                                                        0.035202                                                                            
  Module 5                               hsa03030: DNA replication                                                                   MCM7, RFC4, MCM2, MCM3, FEN1                                                        1.89E-05
  hsa04110: Cell cycle                   CCNB1, MCM7, CDC20, MCM2, MCM3                                                              0.003019                                                                            
  Module 6                               hsa03030: DNA replication                                                                   MCM7, RFC4, MCM2, MCM3, FEN1                                                        1.89E-05
  hsa04110: Cell cycle                   CCNB1, MCM7, CDC20, MCM2, MCM3                                                              0.003019                                                                            
  Module 7                               hsa04510: Focal adhesion                                                                    CAV1, COL4A1, ITGAV, COL6A3, COL3A1, COL1A2, PDGFRB, COL1A1, CTNNB1, FN1            6.85E-07
  hsa04512: ECM-receptor interaction     COL4A1, ITGAV, COL6A3, COL3A1, COL1A2, COL1A1, FN1                                          6.43E-05                                                                            

###### 

Genes nriched in molecular function.

                   Category                                                   Term                                                  Count         \%            P value
  ---------------- ---------------------------------------------------------- ----------------------------------------------------- ------------- ------------- ----------
  Up-regulated     GOTERM_MF_FAT                                              GO: 0048407\~platelet-derived growth factor binding   6             2.941176471   8.41E-08
  GOTERM_MF_FAT    GO: 0005201\~extracellular matrix structural constituent   10                                                    4.901960784   6.22E-07      
  GOTERM_MF_FAT    GO: 0005518\~collagen binding                              7                                                     3.431372549   3.15E-06      
  GOTERM_MF_FAT    GO: 0050840\~extracellular matrix binding                  6                                                     2.941176471   1.27E-05      
  GOTERM_MF_FAT    GO: 0019838\~growth factor binding                         9                                                     4.411764706   2.85E-05      
  Down-regulated   GOTERM_MF_FAT                                              GO: 0000166\~nucleotide binding                       60            30.45685279   1.63E-09
  GOTERM_MF_FAT    GO: 0003723\~RNA binding                                   30                                                    15.2284264    1.09E-08      
  GOTERM_MF_FAT    GO: 0051082\~unfolded protein binding                      13                                                    6.598984772   1.56E-08      
  GOTERM_MF_FAT    GO: 0003735\~structural constituent of ribosome            14                                                    7.106598985   1.40E-07      
  GOTERM_MF_FAT    GO: 0017076\~purine nucleotide binding                     47                                                    23.85786802   3.10E-06      
  GOTERM_MF_FAT    GO: 0030554\~adenyl nucleotide binding                     39                                                    19.79695431   2.68E-05      
  GOTERM_MF_FAT    GO: 0032553\~ribonucleotide binding                        43                                                    21.82741117   3.12E-05      
  GOTERM_MF_FAT    GO: 0032555\~purine ribonucleotide binding                 43                                                    21.82741117   3.12E-05      

###### 

The metabolic pathways of the up-regulated and down-regulated genes.

                   Category                                        Term                                 Count         \%            P value
  ---------------- ----------------------------------------------- ------------------------------------ ------------- ------------- ----------
  Up-regulated     KEGG_PATHWAY                                    hsa04512: ECM-receptor interaction   15            7.352941176   6.48E-11
  KEGG_PATHWAY     hsa04510: Focal adhesion                        17                                   8.333333333   1.64E-07      
  KEGG_PATHWAY     hsa04940: Type I diabetes mellitus              8                                    3.921568627   5.17E-06      
  KEGG_PATHWAY     hsa04612: Antigen processing and presentation   10                                   4.901960784   8.78E-06      
  KEGG_PATHWAY     hsa05330: Allograft rejection                   7                                    3.431372549   2.55E-05      
  KEGG_PATHWAY     hsa05332: Graft-versus-host disease             7                                    3.431372549   4.09E-05      
  Down-regulated   KEGG_PATHWAY                                    hsa03040: Spliceosome                14            7.106598985   1.00E-07
  KEGG_PATHWAY     hsa03050: Proteasome                            8                                    4.060913706   9.62E-06      

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
